Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, AT-8036 Graz, Austria.
Martin
M
Inzinger
Katharina
K
Wippel-Slupetzky
Wolfgang
W
Weger
Leo
L
Richter
Alexander
A
Mlynek
Barbara
B
Fleischander
Christine
C
Scheurecker
Nikolaus
N
Sandor
Daniela
D
Mairhofer
Paul G
PG
Sator
Sabine
S
Moser-Oberthaler
Nina
N
Häring
Petra
P
Viznerova
Clemens
C
Painsi
Adrian
A
Tanew
Peter
P
Ponholzer
Rafaella
R
Tatarski
Wilhelm
W
Brenner
Georg
G
Stingl
Wolfgang
W
Salmhofer
Klemens
K
Rappersberger
Georg
G
Klein
Werner
W
Saxinger
Josef
J
Auböck
Claudia
C
Kölli
Franz
F
Trautinger
Andreas
A
Steiner
Gudrun
G
Ratzinger
Robert
R
Strohal
Elisabeth
E
Riedl
Bernhard
B
Lange-Asschenfeldt
Hubert
H
Pehamberger
Beatrix
B
Volc-Platzer
Sylvia
S
Selhofer
Franz Josef
FJ
Legat
Robert
R
Müllegger
Norbert
N
Reider
Matthias
M
Schmuth
Helmut
H
Hintner
Angelika
A
Hofer
Alexandra
A
Gruber-Wackernagel
Werner
W
Aberer
Franz
F
Quehenberger
Peter
P
Wolf
D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001317:Austria; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D057194:Intention to Treat Analysis; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012042:Registries; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D055815:Young Adult
D001688:Biological Products; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha